$8.88 0.57 (+6.86%)
11/6/2009 4:00 PM

Nektar Therapeutics (NKTR)

CAPS Rating: 3 out of 5

A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.

Current Price $8.88 Mkt Cap $822.8M
Open $8.22 P/E Ratio 0.00
Prev. Close $8.31 Div. (Yield) N/A (N/A)
Daily Range $8.16 - $8.91 Volume 699,094
52-Wk Range $2.93 - $10.64 Avg. Daily Vol. 745,000

NKTR News and Commentary

Caps

How do you think NKTR will perform vs the S&P 500?

Add Stock to Watchlist

All Members

161 Outperform
26 Underperform
 

All-Star Members

38 Outperform
10 Underperform
 

Wall Street

6 Outperform
1 Underperform
 

Top NKTR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TheBotttomFeeder (97.75)
Submitted October 31, 2008

I just noticed how outdated all of the pitches for and against NKTR are. The Exubera debacle is behind them, and people are just waking up to the notion that this is a different company with a bright future.

There are a lot of positives… More

2 Comments | Reply | Report this Post

honcharella (88.83)
Submitted March 14, 2007

This company just can't make a move upward. One of many with this type of technology and also one of many that just fails to produce results in the form of profits. Maybe one day... Just not today.

1 Comment | Reply | Report this Post
NKTR VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about NKTR.

Recs

0
Member Avatar macweb1 (94.76) Submitted: 10/1/2009 12:29:53 PM : Outperform Start Price: $9.46 NKTR Score: -9.16

I'm gambling here. My guess is based on a friend of a friend.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar 4everlost (96.53) Submitted: 4/28/2009 3:44:48 PM : Underperform Start Price: $5.62 NKTR Score: -31.83

The stock price is up 33% over the last year in spite of these terrible #s: Price/Cash Flow = -42.8 Rev. Gwth.
(Last vs. Prior TTM)= -67.0% Profit Margin = -38.1% Ret. on Invest. (TTM) = -7.4% Current Ratio = 5.9
I expect they will use up the money in the bank and struggle to get more.

Report this Post 0 Comments | Reply | Permalink

Recs

2
Member Avatar TheBotttomFeeder (97.75) Submitted: 10/31/2008 4:48:23 PM : Outperform Start Price: $3.65 NKTR Score: +146.66

I just noticed how outdated all of the pitches for and against NKTR are. The Exubera debacle is behind them, and people are just waking up to the notion that this is a different company with a bright future.

There are a lot of positives here: The burn rate has been cut. A recent partnership with Bayer for inhaled Amikacin had very favorable terms. The sale of the pulmonary arm of the company minus some of the most advanced candidates to NVS strengthened NKTR's financial position, and cost them little. Perhaps most importantly, the power and value of their PEGylation platform is just now starting to get some of the attention it deserves. NKTR-102, NKTR-105, NKTR-118, NKTR-119. These are the proprietary drug candidates that could make anybody buying NKTR in the current price range a very happy camper in 3-5 years. NKTR-102, PEG irinotecan, is already showing convincing signs of substantial improvement over the unmodified parent molecule. This combined with the revenue stream expected from the partnered products makes NKTR an extremely undervalued company that few have noticed in the wreckage of the larger market.

Report this Post 2 Comments | Reply | Permalink
View All 41 Pitches »

Leaderboard

Find the members with the highest scoring picks in NKTR.

Score Leader

tkaskmaster

tkaskmaster (91.37) Score: +162.54

The Score Leader is the member with the highest score across all their picks in NKTR.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
tkaskmaster 91.37 6/23/2008 Outperform 1Y $3.60 +146.67% -15.87% +162.54
bone777 47.55 7/10/2008 Outperform 3Y $3.60 +146.67% -10.93% +157.60
TheBotttomFeeder 97.75 9/30/2008 Outperform NS $3.65 +143.29% -3.37% +146.66 3 Comments
Mango777 36.59 7/18/2008 Outperform 5Y $4.01 +121.45% -12.44% +133.89
DOGWRECK < 20 6/5/2008 Outperform 1Y $4.51 +96.90% -19.93% +116.83
b3agle < 20 5/19/2008 Outperform 5Y $4.58 +93.89% -22.80% +116.69 1 Comment
myfirstfund 31.42 5/19/2008 Outperform 1Y $4.57 +94.31% -22.36% +116.67
GreedsGood04 50.11 6/3/2008 Outperform 1Y $4.58 +93.89% -20.25% +114.13
catjtthomas < 20 4/24/2008 Outperform NS $4.60 +93.04% -18.94% +111.98
Randomstocks 56.74 5/9/2008 Outperform 5Y $4.77 +86.16% -20.01% +106.17
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackBMOCapital 86.09 9/23/2009 Outperform NS $10.15 -12.51% +0.05% -12.56
TrackBreanMurray 89.84 6/23/2009 Outperform NS $6.23 +42.54% +20.30% +22.23
TrackWMBlair 39.74 4/7/2009 Outperform NS $5.10 +74.12% +31.60% +42.51
TrackMorganJos < 20 3/24/2009 Outperform NS $4.94 +79.76% +33.24% +46.52
TrackSoros 65.62 9/30/2007 Outperform NS $8.83 -21.40% -13.94% -7.46 3/31/2008 @ $6.94 2 Comments
TrackEveillard 89.92 9/30/2007 Outperform NS $8.83 -21.40% -13.94% -7.46 3/31/2008 @ $6.94 1 Comment
TrackOppenheimer 26.63 3/1/2007 Outperform NS $11.86 -25.13% -19.32% -5.81
TrackDeutscheSec 89.50 3/1/2007 Outperform NS $11.72 -24.23% -19.18% -5.05
TrackJimCramer < 20 8/3/2006 Underperform 3W $16.54 -46.31% -10.46% +35.86
TrackJimCramer < 20 6/21/2006 Outperform 3W $16.99 -2.65% +2.24% -4.89 8/3/2006 @ $16.54
TrackJimCramer < 20 6/19/2006 Underperform 3W $17.42 -2.47% +0.97% +3.44 6/21/2006 @ $16.99
TrackJimCramer < 20 4/27/2006 Outperform 3W $20.69 -15.80% -5.31% -10.49 6/19/2006 @ $17.42

Featured Broker Partners